key: cord-0756239-4oxbczqe authors: Zoghi, Anahita; Ramezani, Mahtab; Roozbeh, Mehrdad; Darzam, Ilad Alavi; Sahraian, Mohammad Ali title: A case of possible atypical demyelinating event of the central nervous system following COVID-19 date: 2020-06-24 journal: Mult Scler Relat Disord DOI: 10.1016/j.msard.2020.102324 sha: 23c1aa025c77909177a1c1ef8c4deeb87f5f521e doc_id: 756239 cord_uid: 4oxbczqe After the novel coronavirus disease outbreak first began in Wuhan, China, in December 2019, the viral epidemic has quickly spread across the world, and it is now a major public health concern. Here we present a 21-year-old male with encephalomyelitis following intermittent vomiting and malaise for 4 days. He reported upper respiratory signs and symptoms 2 weeks before this presentation. Two cerebrospinal fluid (CSF) analyses were notable for mononuclear pleocytosis, elevated protein (more than 100 mg/dl), and hypoglycorrhachia. Brain Magnetic Resonance Imaging (MRI) showed bilateral posterior internal capsule lesions extending to the ventral portion of the pons and a marbled splenium hyperintensity pattern. Cervical and thoracic MRI showed longitudinally extensive transverse myelitis (LETM), none of which were enhanced with gadolinium. Both the AQP4 and MOG antibodies were negative. Spiral chest computed tomography (CT) scan confirmed to COVID-19 as did the high IgG level against coronavirus, but the oropharyngeal swabs were negative. Neurological manifestations of COVID-19 have not been adequately studied. Some COVID-19 patients, especially those suffering from a severe disease, are highly likely to have central nervous system (CNS) manifestations. Our case is a post-COVID-19 demyelinating event in the CNS. Coronavirus neuro-invasive characteristics have been identified in humans. It has been shown that severe infection with SARS-CoV-2 is associated with neurological manifestations such as headache, epilepsy, cerebrovascular events, and encephalitis (Bohmwald et al. 2018 , Asadi-Pooya et al. 2020 . Coronavirus probably enters the CNS through the olfactory bulb, which could cause inflammation and subsequent axonal damage or demyelination (Desforges and et al. 2020 ). We present a young man with COVID-19 and acute encephalomyelitis with newly diagnosed possible demyelinating lesions in the CNS. A previously healthy 21-year-old male with a Bachelor of Science was referred to the emergency room of our hospital on March 20 th , 2020. His family reported that he had a fever with chills, nonproductive cough, and a sore throat 2 weeks before admission, but no hyposmia or hypogeusia. All symptoms decreased in severity within 10 days, after which he developed significant loss of appetite, recurrent vomiting with food intolerance, and generalized malaise. Following 3 days of repeated vomiting, he experienced weakness and paresthesia of the lower limbs, which continued throughout the day. The next day, family members found that he had urinary retention, increased paraparesis severity and weakness in the upper limbs; he also became drowsy. The patient had no headache, vertigo, diplopia, dysphagia, neck pain, or blurred vision. On examination, his blood pressure was 110/85 mmHg, and his pulse was 98 beats per minute. His temperature was 37.9°C, his respiratory rate 20 per minute, and his oxygen saturation 94% while he was breathing ambient air. The patient was lethargic but obeyed simple verbal commands, and there were no evidences of nuchal rigidity, Kernig's or Brudzinski's signs. His pupils were equally reactive to light. The muscular strength was 4+/5 in the upper limbs and 2/5 in the lower limbs. He had normal deep tendon reflexes in all four limbs and Babinski's sign was absent. The position and light touch sensation were impaired in both lower limbs; additionally, he had a T8 sensory level. The abdominal cutaneous reflex was absent in all directions. A spiral chest CT scan revealed the left lung peripheral ground-glass opacities ( Figure 1A ). The patient was transferred to the specialized intensive care unit designated for patients with SARS-CoV-2, and a nasopharyngeal swab was obtained for detection of the COVID-19 genome by a real-time polymerase chain reaction. Initial laboratory tests, as well as erythrocyte sedimentation rate and c-reactive protein, were normal. Screening tests for human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) antibodies and also tests for hepatitis B virus hours after the first tap, showed 250 total nucleated cells per microliter, with 60% lymphocytes. The CSF protein level was 111 mg/dL, and the glucose level was 65 mg/dL. Serologic tests for COVID-19 were requested, which revealed a negative result for IgM, but the IgG level was 1.6 (positive >1.1). At the end of the second week, the upper limb weakness improved, but the force of the lower limbs was 3+/5. The main clinical manifestation of human coronaviruses is respiratory involvement, and the leading cause of death is acute respiratory failure. However, there have been reports of extra respiratory manifestations, such as neurological findings (Ashrafi et al., 2020) . Recent studies suggest possible mechanisms leading to COVID-19 neuroinvasive and neurotropic characteristics. The first is a direct viral injury to the CNS via blood circulation or nasal epithelium (Wu et al., 2020) . Although there are some suggestive case reports of encephalitis (Wu et al., 2020 . Ye et al., 2020 ; there is no definite proof that the SARS-CoV-2 virus directly affects the CNS. The second cause of nervous tissue damage results from the unpredictable effects of the host immune response after an acute infection. Guillain-Barré syndrome (GBS), as peripheral demyelination, is an example of this mechanism. Some cases of COVID-19-related GBS have been reported (Toscano et al., 2020) , but the evidence of causality or effect is weak (Toscano et al., 2020 . Zhao et al., 2020 . The third mechanism is an indirect injury of the CNS due to systemic disease, particularly in patients who are critically ill. The last mechanism is overactivation of the immune response, which results in cytokine release (Yin et al., 2004) . According to the literature, neurotropic coronaviruses could induce a "cytokine storm" by releasing a large number of inflammatory markers (Bohmwald et al., 2018) , which could activate molecular changes and also reactivate immunemediated processes (Kim et al., 2017) . Together, these mechanisms could induce delayed nervous system damage and neurological complications (Klein et al., 2017) . Studies on SARS-CoV-1 revealed a delayed self-reactive T-cell suppression due to viral replication, which leads to neuroinflammation, demyelination or axonal damage of the CNS (Savarin et al., 2017 . Cheng et al., 2019 . Moreover, experimental models of coronavirus-induced neurological disease have shown that sustained CNS inflammation of infected animals correlates with increased demyelination (Savarin et al., 2017) . Recent studies have shown that the novel coronavirus appears to cross the blood-brain barrier and cause acute or delayed CNS demyelination or axonal damage (Desforges et al., 2020) . Acute necrotizing encephalomyelitis following COVID-19 is reported as a case of an acute CNS injury (Poyiadji et al., 2020) . Moreover, a recent report revealed that CNS delayed demyelinating events following COVID-19 . In our case, the absence of symmetric deep-gray matter involving, hemorrhage and cavitation, and also contrast-enhancing lesions (Poyiadji et al., 2020) are more suggestive of demyelination than necrotizing encephalomyelitis. According to our patient's examination, imaging, and laboratory findings, there are two differential diagnoses, including ADEM or Neuromyelitis-Optica spectrum disorder (NMOSD). In the absence of histopathological evidence, we could not settle on an exact diagnosis for the patient. The presenting symptoms, including new-onset fever and drowsiness along with neurological deficit after regressing respiratory illness, suggested a post-viral ADEM; however, in the absence of lesions' enhancement as well as callosal involvement, ADEM is less likely. On the other hand, the history of sudden onset of recurrent vomiting, which could indicate the area of postrema syndrome, along with LETM, and corticospinal tract and corpus callosum hyperintensities are more indicative of NMOSD (Wingerchuk et al., 2015) . Encephalopathy, however, as a presenting symptom and hypoglycorrhachia are uncommon in NMOSD. In the present study, COVID-19 was not detected in CSF or the nasopharynx presumably due to delayed immune-mediated CNS damage that occurred after the virus was cleared. Moreover, this could be explained by the low sensitivity of the system or delayed sampling . Ye et al., 2020 . Severe COVID-19 may affect the CNS and have various acute or delayed neurological complications. During the COVID-19 pandemic, it is important to consider SARS-CoV-2 infection when seeing patients with neurological manifestations, especially those needing immune-modulator therapy, since the established recommendations are insufficient at this time. Central nervous system manifestations of COVID-19: A systematic review Coronavirus, Its Neurologic Manifestations, and Complications Neurologic alterations due to respiratory virus infections Innate immune responses and Viral-Induced neurologic disease Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System Neurological complications during treatment of Middle East respiratory syndrome Infectious immunity in the central nervous system and brain function SARS-CoV-2:"Three-steps" infection model and CSF diagnostic implication COVID-19-associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features Viral-induced suppression of self-reactive T cells: Lessons from neurotropic coronavirus-induced demyelination Guillain-Barré Syndrome Associated with SARS-CoV-2 International consensus diagnostic criteria for neuromyelitis optica spectrum disorders Nervous system involvement after infection with COVID-19 and other coronaviruses Encephalitis as a clinical manifestation of COVID-19 Clinical analysis of multiple organ dysfunction syndrome in patients suffering from SARS SARS-CoV-2 can induce brain and spine demyelinating lesions Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? This study received no funds. Role of Funding Source: None.